Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 431

Sort by

Sort Order Select

Journal Articles

An IgA plasmacytoma: a rare and distinct form of plasmacytoma

Huan-You Wang, Aaron M. Goodman

Blood (2020) 135 (17): 1505.

https://doi.org/10.1182/blood.2020004978

Published: 2020

Journal Articles

Cutaneous plasmablastic plasmacytoma

Alfred Chung, Michaela Liedtke

Blood (2019) 134 (23): 2116.

https://doi.org/10.1182/blood.2019002821

Published: 2019

Journal Articles

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Rafael Fonseca, MD, May Hagiwara, PhD, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Jacqueline Buchanan, Thomas Delea, MBA

Blood (2019) 134 (Supplement_1): 2211.

https://doi.org/10.1182/blood-2019-123743

Published: 2019

Journal Articles

Disparities in Plasma Cell Neoplasms in Kentucky, Appalachia and Other States: A Population Based Study

Ayman Qasrawi, MD, Richard L O'Neal, MD, Maxwell M. Krem, MD PhD, Gregory Monohan, MD, Reinhold Munker, MD, Gerhard C. Hildebrandt, MD

Blood (2019) 134 (Supplement_1): 4735.

https://doi.org/10.1182/blood-2019-127687

Published: 2019

Journal Articles

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 605.

https://doi.org/10.1182/blood-2019-125588

Published: 2019

Journal Articles

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Akira Honda, MD PhD, Yu Oyama, MD, Kazuhiro Toyama, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 5492.

https://doi.org/10.1182/blood-2019-129324

Published: 2019

Journal Articles

Clinical Utility of B- and T-Cell Gene Rearrangement Studies in Blood and Bone Marrow Samples

Hadrian Mendoza, BS, Christopher Tormey, MD, Alexa J. Siddon, MD

Blood (2019) 134 (Supplement_1): 5223.

https://doi.org/10.1182/blood-2019-121747

Published: 2019

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

Naomi Aoki, MSc, BSc, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Zoe McQuilten, Cameron Wellard, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2019) 134 (Supplement_1): 5518.

https://doi.org/10.1182/blood-2019-124256

Published: 2019

Journal Articles

[ 18 f]-( 2S , 4R )-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma

Nicola Giuliani, Silvia Valtorta, PhD, Martina Chiu, PhD, Denise Toscani, PhD, Andrea Sartori, PhD, Angela Coliva, PhD, Arianna Brevi, Stefania Battaglia, MS, Emanuela Vicario, PhD, Giuseppe Taurino, MS, Matteo Grioni, Francesca Ferlenghi, PhD, Livia Ruffini, MD, Federica Vacondio, PhD, Franca Zanardi, PhD, Matteo Bellone, MD, Rosa Maria Moresco, PhD, Ovidio Bussolati, MD PhD

Blood (2019) 134 (Supplement_1): 5542.

https://doi.org/10.1182/blood-2019-127935

Published: 2019

Journal Articles

Incidence and Outcomes of Extramedullary Myeloma in a South Australian Hospital

Angelina Yong, BSc,BMBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 5504.

https://doi.org/10.1182/blood-2019-129754

Published: 2019

Journal Articles

Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers

Camila Peña, MD, Natalia Paola Schutz, MDMSc, Virginia Bove, MD, Fiorella Villano, MD, Rocío Osorio, MD, Mauricio Chandia, MD, Cecilia Beltran, MD, Javier Schulz, MD, Daniela Cardemil, MD, Carolina Contreras, MD, Carmen Gloria Vergara, MD, Javiera Donoso, MD, Marcela Espinoza, MD, Gabriel La Rocca, MD, Hernán López-Vidal, MD, Pilar León, MD, Christine Rojas, MD, Pablo Soto, MD, Sandra Aranda, MD, Vivianne Torres, MD, Paola Ochoa, MD, Patricio Duarte, MD, Guillermina Remaggi, MD, Sebastian Yantorno, MD, Ariel Corzo, MD, Soledad Zabaljauregui, MD, Claudia Shanley, MD, Sergio Lopresti, MD, Sergio Orlando, MD, Veronica Verri, MD, Luis Darío Quiroga, MD, Carlos García, MD, Vanesa Fernandez, MD, Dorotea Fantl, MD, Jhoanna Ramirez, MD, Alicia Molina, MD, Pilar Papilco, MD, Alex Mite, MD, Ines Reyes, MD, Brener Sabando, MD, Francisca M. Ramirez Aspiazu, MD, Claudia Lucia Sossa, MD, Virginia Abello, MD, Henry Idrobo, MD Professor, Kenny Galvez, MD, Domingo Saavedra, MD, Guillermo Quintero, MD MBA, Raimundo Gazitua, MD, Lina Gaviria, MD, Rigoberto Gomez, MD, Monica Osuna Pérez, MD, Alicia Henao-Uribe, MD, Luz del Carmen Tarín Arzaga, MD, Omar Cantú-Martínez, MD, David Gomez-Almaguer, MD, Yarely Itzayana García-Navarrete, MD, Antonio Cruz-Mora, MD, Yahveth Cantero-Fortiz, MD, Guillermo J. Ruiz-Arguelles, FRCP, MACP, Macarena Roa, MD, Eloisa Riva, MD

Blood (2019) 134 (Supplement_1): 5497.

https://doi.org/10.1182/blood-2019-127555

Published: 2019

Journal Articles

Real World Outcomes in Latin-American Patients with Multiple Myeloma Under 40 Years Old

Humberto Martínez-Cordero, MD, Camila Peña, MD, Natalia Paola Schutz, MDMSc, Virginia Bove, MD, Fiorella Villano, MD, Rocío Osorio, MD, Mauricio Chandia, MD, Cecilia Beltran, MD, Javier Schulz, MD, Daniela Cardemil, MD, Carolina Contreras, MD, Carmen Gloria Vergara, MD, Javiera Donoso, MD, Marcela Espinoza, MD, Gabriel La Rocca, MD, Hernán López-Vidal, MD, Pilar León, MD, Macarena Alejandra Roa Salinas, Christine Rojas, MD, Pablo Soto, MD, Sandra Aranda, MD, Vivianne Torres, MD, Paola Ochoa, MD, Patricio Duarte, MD, Guillermina Remaggi, MD, Sebastian Yantorno, MD, Ariel Corzo, MD, Soledad Zabaljauregui, MD, Claudia Shanley, MD, Sergio Lopresti, MD, Sergio Orlando, MD, Veronica Verri, MD, Luis Darío Quiroga, MD, Juan Jose Garcia, MD, Vanesa Fernandez, MD, Dorotea Fantl, MD, Jhoanna Ramirez, MD, Alicia Molina, MD, Pilar Papilco, MD, Alex Mite, MD, Ines Reyes, MD, Brenner Sabando, Francisca M. Ramirez Aspiazu, MD, Claudia Lucia Sossa, MD, Virginia Abello, MD, Henry Idrobo, MD Professor, Domingo Saavedra, MD, Guillermo Quintero, MD MBA, Lina Gaviria, MD, Rigoberto Gomez, MD, Monica Osuna Pérez, MD, Alicia Henao-Uribe, MD, Luz del Carmen Tarín Arzaga, MD, Omar Cantú-Martínez, MD, David Gomez-Almaguer, MD, Yarely Itzayana García-Navarrete, MD, Antonio Cruz-Mora, MD, Yahveth Cantero-Fortiz, MD, Guillermo J. Ruiz-Arguelles, FRCP, MACP, Eloisa Riva, MD

Blood (2019) 134 (Supplement_1): 5508.

https://doi.org/10.1182/blood-2019-130987

Published: 2019

Journal Articles

Impact of Osseous and Non-Osseous Extramedullary Disease in Multiple Myeloma: Clinical Characteristics and Outcomes in a Latin American Population

Cesar Vargas-Serafin, MD, Aldo A Acosta-Medina, MS, Juan Rangel-Patiño, MD, Daniela Perez-Samano, MD, Deborah M. Martinez-Banos, Christianne Bourlon, MD

Blood (2019) 134 (Supplement_1): 5527.

https://doi.org/10.1182/blood-2019-128791

Published: 2019

Journal Articles

Real Life Use of Imaging in the Management of Newly Diagnosed Patients with Myeloma- Practical Perspectives from a UK Hospital

Ke Xu, MD, Lucy Fowkes, Fenella Willis, Yasmin Reyal

Blood (2019) 134 (Supplement_1): 5513.

https://doi.org/10.1182/blood-2019-121504

Published: 2019

Journal Articles

Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients

Jingjing Shang, Weiqin Yao, Lingzhi Yan, Xiaolan Shi, Ruju Wang, Shuang Yan, Yong Liu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 1855.

https://doi.org/10.1182/blood-2019-129434

Published: 2019

Journal Articles

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

David G. Coffey, MD, Andrew J. Cowan, MD, Timothy S Martins, PhD, Damian J. Green, MD, Edward N. Libby, III, MD, Rebecca W. Silbermann, MD, Sylvia Chien, Jin Dai, PhD, Alicia Morales, Niall Curley, Bret Gary Degraaff, BS, Ted A Gooley, PhD, Edus H. Warren, MD PhD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 1885.

https://doi.org/10.1182/blood-2019-125383

Published: 2019

Journal Articles

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Smith Giri, MBBS, Peter Barth, MD, Luciano J. Costa, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 1862.

https://doi.org/10.1182/blood-2019-131231

Published: 2019

Journal Articles

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel-Dedieu, Bernard Sebastien, Hoai-Thu Thai, Raouf El-Cheikh, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Li Liu, Frank Campana, MD, Helgi van de Velde, MD PhD, Christine Veyrat-Follet, Dorothee Semiond, PhD PharmD

Blood (2019) 134 (Supplement_1): 1897.

https://doi.org/10.1182/blood-2019-128875

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset

Blood (2019) 134 (Supplement_1): 2130.

https://doi.org/10.1182/blood-2019-125640

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

An IgA plasmacytoma: a rare and distinct form of plasmacytoma

Cutaneous plasmablastic plasmacytoma

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Disparities in Plasma Cell Neoplasms in Kentucky, Appalachia and Other States: A Population Based Study

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Clinical Utility of B- and T-Cell Gene Rearrangement Studies in Blood and Bone Marrow Samples

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

[ 18 f]-( 2S , 4R )-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma

Incidence and Outcomes of Extramedullary Myeloma in a South Australian Hospital

Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers

Real World Outcomes in Latin-American Patients with Multiple Myeloma Under 40 Years Old

Impact of Osseous and Non-Osseous Extramedullary Disease in Multiple Myeloma: Clinical Characteristics and Outcomes in a Latin American Population

Real Life Use of Imaging in the Management of Newly Diagnosed Patients with Myeloma- Practical Perspectives from a UK Hospital

Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only